Nicole Lamanna
Overview
Explore the profile of Nicole Lamanna including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
86
Citations
2914
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kater A, Harrup R, Kipps T, Eichhorst B, Owen C, Assouline S, et al.
Blood
. 2025 Feb;
PMID: 40009494
Fixed-duration venetoclax-rituximab (VenR) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) in the phase 3 MURANO trial (NCT02005471) resulted in superior progression-free survival (PFS) and overall survival (OS) vs bendamustine-rituximab...
2.
Brown J, Li J, Eichhorst B, Lamanna N, OBrien M.D S, Tam C, et al.
Blood Adv
. 2025 Jan;
PMID: 39853273
Some CLL patients who develop progressive disease (PD) during treatment with covalent Bruton tyrosine kinase inhibitors (cBTKi) acquire pathway resistance mutations in BTK or PLCG2. Here, we report gene mutation...
3.
Lipsky A, Lamanna N
Clin Lymphoma Myeloma Leuk
. 2024 Dec;
PMID: 39732538
In the past decade, the treatment paradigm for chronic lymphocytic leukemia (CLL) has markedly shifted from traditional chemoimmunotherapy towards targeted therapies. A fixed-duration, targeted regimen with venetoclax, a potent oral...
4.
Ghosh N, Eyre T, Brown J, Lamanna N, Manzoor B, Coombs C, et al.
Am J Hematol
. 2024 Dec;
100(3):511-515.
PMID: 39698781
No abstract available.
5.
Lamanna N, Tam C, Woyach J, Alencar A, Palomba M, Zinzani P, et al.
EJHaem
. 2024 Oct;
5(5):929-939.
PMID: 39415923
Clinical bleeding events are reported here from 773 patients with B-cell malignancies receiving pirtobrutinib monotherapy from the phase 1/2 BRUIN study (ClinicalTrials.gov identifier: NCT03740529), either in the presence or absence...
6.
Shah N, Wang M, Roeker L, Patel K, Woyach J, Wierda W, et al.
Haematologica
. 2024 Oct;
110(1):92-102.
PMID: 39363864
Bruton tyrosine kinase inhibitors (BTKi) have transformed the treatment of B-cell malignancies, but intolerance has often led to their discontinuation. The phase I/II BRUIN study evaluated pirtobrutinib, a highly selective...
7.
Brown J, Eichhorst B, Lamanna N, OBrien S, Tam C, Qiu L, et al.
Blood
. 2024 Sep;
144(26):2706-2717.
PMID: 39316666
The ALPINE trial established the superiority of zanubrutinib over ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma; here, we present data from the final comparative analysis...
8.
Wierda W, Shah N, Cheah C, Lewis D, Hoffmann M, Coombs C, et al.
Lancet Haematol
. 2024 Jul;
11(9):e682-e692.
PMID: 39033770
Background: Richter transformation usually presents as an aggressive diffuse large B-cell lymphoma, occurs in up to 10% of patients with chronic lymphocytic leukaemia, has no approved therapies, and is associated...
9.
Roeker L, Woyach J, Cheah C, Coombs C, Shah N, Wierda W, et al.
Blood
. 2024 Jun;
144(13):1374-1386.
PMID: 38861666
Pirtobrutinib is a highly selective, noncovalent (reversible) Bruton tyrosine kinase inhibitor (BTKi). Patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) were treated with fixed-duration pirtobrutinib plus venetoclax (PV)...
10.
Shadman M, Tedeschi A, Mohseninejad L, Yang K, Lamanna N, Xu S, et al.
Blood Cancer J
. 2024 May;
14(1):77.
PMID: 38697986
No abstract available.